Our ultimate goal is to discover at least one new antibiotic class and to draft at least one partnership agreement with a leading public-private partnership on antibiotic resistance. The new compound (s) is (are) preferably oriented towards the market of hospital infections and should (and), to have an immediate market value, preferably be used for the treatment of hospital-acquired pneumonia, urinary tract infections, postoperative wound infections and / or bloodstream infections.